Nivolumab combined with brentuximab vedotin (BV) for relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL): Efficacy and safety results from the phase 2 CheckMate 436 study Meeting Abstract


Authors: Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta-Shah, N. A.; Manley, T.; Francis, S.; Sharma, M.; Moskowitz, A. J.
Abstract Title: Nivolumab combined with brentuximab vedotin (BV) for relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL): Efficacy and safety results from the phase 2 CheckMate 436 study
Meeting Title: 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019)
Keywords: lymphoma; relapsed/refractory; hodgkin; brentuximab vedotin; nivolumab; hl; primary mediastinal large b-cell lymphoma (pmbl); pmbl
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 19
Issue: Suppl. 1
Meeting Dates: 2019 Sep 11-14
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2019-09-01
Start Page: S303
Language: English
ACCESSION: WOS:000483480700298
DOI: 10.1016/j.clml.2019.07.262
PROVIDER: wos
Notes: Meeting Abstract: HL-078 -- Source: Wos
Altmetric Score
MSK Authors
  1. Alison Moskowitz
    165 Moskowitz